| Shaakira Lateefa Abdullah, | |
|
501 W 14th St, Wilmington, DE 19801-1013 | |
| (302) 428-4410 | |
| (302) 428-4078 |
| Full Name | Shaakira Lateefa Abdullah |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 501 W 14th St, Wilmington, Delaware |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073028189 | NPI | - | NPPES |
| Entity Name | Christiana Care Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770568107 PECOS PAC ID: 9739097569 Enrollment ID: O20031201000477 |
News Archive
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the United States Food and Drug Administration informed CTI that due to severe weather conditions in the Washington, D.C. area, the FDA is postponing the Oncologic Drugs Advisory Committee ("ODAC") meeting that was to be held on Wednesday, February 10, 2010 to discuss the pixantrone New Drug Application ("NDA"). The FDA indicated that it intends to reschedule the meeting as soon as the FDA can determine a schedule that will allow them to reconvene the advisory panel.
OrbusNeich announced that clinical data presented at the Joint Intervention Meeting (JIM) 2010 in Rome provide further evidence that the company's Genous stent could be a treatment of choice for patients not suitable for long term dual antiplatelet therapy. The investigator initiated, 50 patient, multicenter study evaluated the safety of patients receiving only 10 days dual antiplatelet therapy undergoing stenting with the Genous Bio-engineered R stent. The primary endpoint was the absence of stent thrombosis or any occlusion within three months.
"Despite Americans' poor lifestyle choices and the chronic problems they spawn, the health-care reform proposals being considered in Congress contain relatively little to promote wellness," The Tennessean reports.
Unravelling the entire genetic code for each child who has been diagnosed with cancer can give a more accurate diagnosis or reveal new treatment options, according to research presented at the NCRI Festival. These are the results of a pilot study of the process known as whole genome sequencing.
› Verified 5 days ago
| Entity Name | Christiana Care Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1760811681 PECOS PAC ID: 9739097569 Enrollment ID: O20150120001440 |
News Archive
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the United States Food and Drug Administration informed CTI that due to severe weather conditions in the Washington, D.C. area, the FDA is postponing the Oncologic Drugs Advisory Committee ("ODAC") meeting that was to be held on Wednesday, February 10, 2010 to discuss the pixantrone New Drug Application ("NDA"). The FDA indicated that it intends to reschedule the meeting as soon as the FDA can determine a schedule that will allow them to reconvene the advisory panel.
OrbusNeich announced that clinical data presented at the Joint Intervention Meeting (JIM) 2010 in Rome provide further evidence that the company's Genous stent could be a treatment of choice for patients not suitable for long term dual antiplatelet therapy. The investigator initiated, 50 patient, multicenter study evaluated the safety of patients receiving only 10 days dual antiplatelet therapy undergoing stenting with the Genous Bio-engineered R stent. The primary endpoint was the absence of stent thrombosis or any occlusion within three months.
"Despite Americans' poor lifestyle choices and the chronic problems they spawn, the health-care reform proposals being considered in Congress contain relatively little to promote wellness," The Tennessean reports.
Unravelling the entire genetic code for each child who has been diagnosed with cancer can give a more accurate diagnosis or reveal new treatment options, according to research presented at the NCRI Festival. These are the results of a pilot study of the process known as whole genome sequencing.
› Verified 5 days ago
| Entity Name | Signify Health Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689158487 PECOS PAC ID: 3274895263 Enrollment ID: O20210215001302 |
News Archive
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the United States Food and Drug Administration informed CTI that due to severe weather conditions in the Washington, D.C. area, the FDA is postponing the Oncologic Drugs Advisory Committee ("ODAC") meeting that was to be held on Wednesday, February 10, 2010 to discuss the pixantrone New Drug Application ("NDA"). The FDA indicated that it intends to reschedule the meeting as soon as the FDA can determine a schedule that will allow them to reconvene the advisory panel.
OrbusNeich announced that clinical data presented at the Joint Intervention Meeting (JIM) 2010 in Rome provide further evidence that the company's Genous stent could be a treatment of choice for patients not suitable for long term dual antiplatelet therapy. The investigator initiated, 50 patient, multicenter study evaluated the safety of patients receiving only 10 days dual antiplatelet therapy undergoing stenting with the Genous Bio-engineered R stent. The primary endpoint was the absence of stent thrombosis or any occlusion within three months.
"Despite Americans' poor lifestyle choices and the chronic problems they spawn, the health-care reform proposals being considered in Congress contain relatively little to promote wellness," The Tennessean reports.
Unravelling the entire genetic code for each child who has been diagnosed with cancer can give a more accurate diagnosis or reveal new treatment options, according to research presented at the NCRI Festival. These are the results of a pilot study of the process known as whole genome sequencing.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shaakira Lateefa Abdullah, 342 Macdonald Close, Bear, DE 19701-8303 Ph: (908) 721-6039 | Shaakira Lateefa Abdullah, 501 W 14th St, Wilmington, DE 19801-1013 Ph: (302) 428-4410 |
News Archive
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the United States Food and Drug Administration informed CTI that due to severe weather conditions in the Washington, D.C. area, the FDA is postponing the Oncologic Drugs Advisory Committee ("ODAC") meeting that was to be held on Wednesday, February 10, 2010 to discuss the pixantrone New Drug Application ("NDA"). The FDA indicated that it intends to reschedule the meeting as soon as the FDA can determine a schedule that will allow them to reconvene the advisory panel.
OrbusNeich announced that clinical data presented at the Joint Intervention Meeting (JIM) 2010 in Rome provide further evidence that the company's Genous stent could be a treatment of choice for patients not suitable for long term dual antiplatelet therapy. The investigator initiated, 50 patient, multicenter study evaluated the safety of patients receiving only 10 days dual antiplatelet therapy undergoing stenting with the Genous Bio-engineered R stent. The primary endpoint was the absence of stent thrombosis or any occlusion within three months.
"Despite Americans' poor lifestyle choices and the chronic problems they spawn, the health-care reform proposals being considered in Congress contain relatively little to promote wellness," The Tennessean reports.
Unravelling the entire genetic code for each child who has been diagnosed with cancer can give a more accurate diagnosis or reveal new treatment options, according to research presented at the NCRI Festival. These are the results of a pilot study of the process known as whole genome sequencing.
› Verified 5 days ago
Geetanjali Chatterjee, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1400 N Washington St Ste 300, Wilmington, DE 19801 Phone: 302-320-5700 | |
Ms. Janine M. Catanach, APN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1600 Rockland Rd, Alfred I. Dupont Hospital For Children, Wilmington, DE 19803 Phone: 302-651-4000 Fax: 302-651-5068 | |
Mr. Kristopher Starr, APN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 501 W 14th St, Emergency Department, Wilmington, DE 19801 Phone: 302-320-4180 Fax: 302-575-1714 | |
Miss Nadine Lindsay, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1718 Marsh Rd, Wilmington, DE 19810 Phone: 302-478-7200 | |
Olamide Abiodun Vincent, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 5215 Concord Pike, Wilmington, DE 19803 Phone: 484-408-5168 Fax: 877-383-8544 | |
Michelle Lauer, PMHNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3521 Silverside Rd Ste 2f1, Wilmington, DE 19810 Phone: 302-224-1400 | |
Aimee Stumpo, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1601 Concord Pike Ste 78, Wilmington, DE 19803 Phone: 302-887-1266 |